6,249 Shares in Cencora, Inc. $COR Purchased by Fairtree Asset Management Pty Ltd

Fairtree Asset Management Pty Ltd acquired a new stake in Cencora, Inc. (NYSE:COR) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,249 shares of the company’s stock, valued at approximately $1,768,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Kemnay Advisory Services Inc. bought a new position in Cencora during the fourth quarter worth $25,000. Oakworth Capital Inc. bought a new stake in Cencora during the fourth quarter valued at $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora during the fourth quarter worth $27,000. Archer Investment Corp raised its holdings in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the period. Finally, Motiv8 Investments LLC bought a new position in shares of Cencora in the 4th quarter worth about $29,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other news, Director Lauren M. Tyler bought 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average price of $270.23 per share, with a total value of $148,626.50. Following the completion of the acquisition, the director directly owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.38% of the stock is owned by corporate insiders.

Cencora Stock Performance

Shares of COR stock opened at $315.15 on Friday. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. The firm has a market capitalization of $60.14 billion, a price-to-earnings ratio of 23.41, a price-to-earnings-growth ratio of 1.82 and a beta of 0.57. The business has a 50 day simple moving average of $301.86 and a 200 day simple moving average of $311.85.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.35 by $0.13. The company had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.00 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 17.87 EPS for the current year.

Cencora announced that its board has approved a share buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 14th. Cencora’s dividend payout ratio (DPR) is currently 17.83%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on COR shares. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, August 6th. Morgan Stanley raised their target price on shares of Cencora from $342.00 to $346.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Barclays decreased their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research note on Wednesday, June 10th. Citigroup reissued a “buy” rating on shares of Cencora in a report on Thursday, August 6th. Finally, Royal Bank Of Canada started coverage on Cencora in a research report on Wednesday. They issued a “sector perform” rating and a $330.00 target price on the stock. Thirteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $370.85.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.